Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT536 + amivantamab
- Development stage
- Unknown
- Lead developer
- Fate Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**FT536 + amivantamab** is an investigational combination therapy being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, particularly locally advanced or metastatic non-small cell lung cancer (NSCLC)[1]. FT536 is an off-the-shelf, allogeneic, chimeric antigen receptor (CAR)-engineered NK cell therapy, designed to enhance anti-tumor activity and persistence after infusion. Amivantamab is a fully human bispecific IgG1 monoclonal antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), blocking ligand binding and receptor signaling, thus inhibiting cancer cell growth and survival. Amivantamab also mediates immune effector functions including antibody-dependent cell-mediated cytotoxicity (ADCC)[2]. The combination is being developed to leverage the synergistic effects of FT536’s innate immune action and amivantamab’s dual targeting and ADCC induction, particularly in NSCLC cohorts after lymphodepletion[1][2].
- Other names
- amivantamab-vmjw
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on FT536 + amivantamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT536 + amivantamab.